Six of eight patients with nonactive secondary progressive multiple sclerosis (SPMS) being treated with foralumab nasal spray — all part of an intermediate-size expanded access program (EAP) allowing the therapy’s use — have experienced reductions in their fatigue levels.
That’s according to treatment developer Tiziana Life Sciences, which is reporting data from positron emission tomography (PET) scans obtained at three months of treatment.
Those scans also revealed that the same six patients had a reduction in the activity of microglia, the brain’s resident immune cells, which are known to contribute to disease progression in multiple sclerosis.
A total of 10 patients are now being followed as part of foralumab’s expanded access programs, which are taking place at Brigham and Women’s Hospital, in Boston. PET scans for the two additional patients should be available later this month, the company said.
“These findings are promising from an imaging standpoint and further studies are needed to confirm them using additional quantitative approaches,” Tarun Singhal, MD, who directs the PET Imaging Program in Neurologic Diseases at Brigham and Women’s Hospital, said in a Tiziana press release. Read more HERE…